Key facts
- This page summarizes Pavan Cheruvu's Form 4 filing for Sio Gene Therapies Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Dec 2021, 17:31.
Pavan Cheruvu - 08 Dec 2021 Form 4 Insider Report for Sio Gene Therapies Inc.
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 08 Dec 2021
- Net transaction value
- -$21,135
- SEC form
- 4
- Accepted by SEC
- 09 Dec 2021, 17:31:14 UTC
- Next SEC filing
- 19 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Nassif, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Pavan Cheruvu filed Form 4 for Sio Gene Therapies Inc. on 09 Dec 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$21,135.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SIOX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +37,567
- Change %
- +21%
- Price
- $0.000000
- Shares after
- 217,993
- Date
- 08 Dec 2021
- Ownership
- Direct
SIOX
transaction
Common Stock
Tax liability
- Transaction value
- $21,135
- Shares
- -14,884
- Change %
- -6.8%
- Price
- $1.42
- Shares after
- 203,109
- Date
- 08 Dec 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SIOX
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- $0
- Shares
- -37,567
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 75,133
- Date
- 08 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,567
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units.
Footnote F2
Each restricted stock unit represents the right to receive one share of the Issuer's common stock. The shares of common stock underlying the restricted stock units vested on April 15, 2021 but settlement of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.
Footnote F3
50% of the shares of common stock underlying the remaining restricted stock units vest on April 15, 2022 and the remainder vest on April 15, 2023, subject to the Reporting Person providing continuous service to the Issuer through each such date.